A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia is driving better survival and cure rates.
Substantial delays are taking place across the cancer care pathway in Nepal, with many patients waiting months between first symptoms and treatment, according to an article by the International Agency for Research on Cancer and partners.
GLP-1 receptor agonists—the class of drugs behind Ozempic, Wegovy, and Mounjaro—may do more than regulate blood sugar and weight.
About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a KFF Health Tracking Poll finds.
Clinician-scientists at St. Jude Children’s Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.
A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive soft tissue cancer that occurs most often in pediatric and young adult patients.
Nuvalent, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced positive topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 phase I/II clinical trial.
Limited access to digital resources may be one reason why rural cancer survivors are underrepresented in cancer research, according to researchers at the University of Arkansas for Medical Sciences Institute for Community Health Innovation.
Xilio Therapeutics announced data from its ongoing Phase II clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq) in patients with microsatellite stable metastatic colorectal cancer.
The Alliance for Clinical Trials in Oncology has launched a new clinical trial seeking to evaluate the feasibility of delivering a structured exercise program entirely through telehealth for patients with cancer receiving chemotherapy with the ultimate goal of reducing fatigue and disability.
